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Summary
QUESTION UNDER STUDY: The aim of this study was
to assess the prevalence of chronic kidney disease (CKD)
among type 2 diabetic patients in primary care settings in
Switzerland, and to analyse the prescription of antidiabet-
ic drugs in CKD according to the prevailing recommenda-
tions.
METHODS: In this cross-sectional study, each participat-
ing physician was asked to introduce anonymously in a
web database the data from up to 15 consecutive diabetic
patients attending her/his office between December 2013
and June 2014. Demographic, clinical and biochemical
data were analysed. CKD was classified with the KDIGO
nomenclature based on estimated glomerular filtration rate
(eGFR) and urinary albumin/creatinine ratio.
RESULTS: A total of 1 359 patients (mean age 66.5 ±
12.4 years) were included by 109 primary care physicians.
CKD stages 3a, 3b and 4 were present in 13.9%, 6.1%,
and 2.4% of patients, respectively. Only 30.6% of patients
had an entry for urinary albumin/creatinine ratio. Among
them, 35.6% were in CKD stage A2, and 4.1% in stage A3.
Despite prevailing limitations, metformin and sulfonylur-
eas were prescribed in 53.9% and 16.5%, respectively, of
patients with advanced CKD (eGFR <30 ml/min). More
than a third of patients were on a dipeptidyl-peptidase-4 in-
hibitor across all CKD stages. Insulin use increased pro-
gressively from 26.8% in CKD stage 1–2 to 50% in stage
4.
CONCLUSIONS: CKD is frequent in patients with type 2
diabetes attending Swiss primary care practices, with CKD
stage 3 and 4 affecting 22.4% of cases. This emphasizes the
Abbreviations
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CKD-EPI Chronic Kidney Disease-Epidemiology Collaboration
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KDIGO Kidney Disease: Improving Global Outcomes
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importance of routine screening of diabetic nephropathy
based on both eGFR and urinary albumin/creatinine ratio,
the latter being largely underused by primary care phys-
icians. A careful individual drug risk/benefit balance as-
sessment is mandatory to avoid the frequently observed
inappropriate prescription of antidiabetic drugs in CKD pa-
tients.
Key words: type 2 diabetes; chronic kidney disease;
antidiabetic drugs; primary care
Introduction
Chronic kidney disease (CKD) in diabetic patients is on the
rise owing to the increased prevalence of type 2 diabetes
(T2D) and the aging population [1]. However, we are lack-
ing data for the prevalence of CKD in the diabetic popula-
tion followed-up by primary care physicians in Switzerland
although it is well recognised that in the last decades dia-
betic nephropathy has become one of the leading causes of
end-stage renal disease.
In Switzerland, recommendations for the use of antidia-
betic drugs in CKD were elaborated in 2012 by the Swiss
Society of Endocrinology and Diabetology (SSED) [2].
Whether these recommendations have reached PCPs and
are followed by them is not clear and has never been eval-
uated. Therefore, the goal of this cross-sectional study was
to examine the prevalence of CKD stages in T2D patients
followed-up by PCPs in Switzerland and to examine ac-
cordingly the prescription of antidiabetic drugs.
Methods
Data were collected from December 2013 to June 2014 in
Switzerland by performing a cross-sectional survey of am-
bulatory diabetic patients visiting their physicians. The cri-
terion for recruitment was T2D. An exclusion criterion was
type 1 diabetes. Randomisation of participating physicians
was as follows: for the German and French linguistic re-
gions of Switzerland, around 109 physicians were recruited
randomly among general practitioners and internists. No
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 1 of 12
physician from the Italian-speaking part of Switzerland
was included in the study. The participating physicians
were asked to collect the data from up to 15 consecutive
diabetic patients. The data were entered anonymously in a
web database elaborated by PNN AG (www.pnn.ch). One
hundred and nine physicians participated in the survey.
Each participating physician received 30 CHF per included
patient. The maximum amount paid was 450 CHF (for 15
patients) even if the physician included more than 15 pa-
tients. Informed consent was obtained from each patient.
Demographic and clinical data, complications related to
diabetes and details of antidiabetic, antihypertensive and
lipid lowering therapies and aspirin treatment were col-
lected using a standardised web questionnaire. Estimated
glomerular filtration rate (eGFR) was calculated with the
Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) formula [3]. The age-related eGFR decline was
estimated using simple linear regression stratified by sex.
For the evaluation of albuminuria, only the albumin/cre-
atinine ratio (ACR) was considered for classification, in
accordance with Kidney Disease: Improving Global Out-
comes (KDIGO) [3] as shown in table 1. In this manuscript
we report the data for CKD stages and detailed antidiabetic
therapy. The history of hypoglycaemia was assessed by
asking patients to rate the frequency of hypoglycaemic
events according to the following categorisation: never,
low, medium and high.
This study was supported by Boehringer Ingelheim and
Lilly for the logistics of data collection but not for data ana-
lysis and manuscript preparation, which was performed in-
dependently by the authors. The study was approved by the
Ethics Committee of the Canton de Vaud.
Results
In the German-speaking region of Switzerland, 134 phys-
icians were willing to participate (134/4097 = 3.2% of
primary care physicians including general medicine, in-
ternal medicine and general internal medicine). Among
them, 76 finally introduced at least one case in the database
(76/134 = 56.7%). In the French-speaking regions of
Switzerland, 61 physicians were willing to participate (61/
1416 = 4.3% of primary care physicians (including general
medicine, internal medicine and general internal medicine).
Among them, 33 finally introduced at least one case in
the web database (33/61 = 54%). The representation of
primary care physicians per population was similar in the
German- and French-speaking regions. Finally, a total of
109 primary care physicians from 20 German- or French-
speaking cantons participated in the study with a total of
1359 patients included for analysis. The characteristics of
enrolled patients are presented in table 2. There were a ma-
jority of male and Caucasian patients. Average age was of
66.5 ± 12.4 years (mean ± standard deviation [SD]) with
the majority (57.5%) being in the 60–80 year age group.
Mean duration of diabetes was 9.3 years and mean body
mass index (BMI) was 30.2 kg/m2, with only 16% having
a normal BMI.
Stages of chronic kidney disease
The distribution of eGFR according to the CKD-EPI equa-
tion is presented in table 2. Since dose adaptation of oral
Figure 1
Beta coefficient and standard error (SE) from simple linear
regression.
CI = confidence interval; CKD-EPI = chronic kidney disease-
epidemiology collaboration





Moderately increased Severely increased
Prognosis of CKD by eGFR and ACR
ACR <3 mg/mmol 3–30 mg/mmol >30 mg/mmol
G1 Normal or high ≥90 +/– + ++
G2 Mildly decreased 60–89 +/– + ++
G3a Mildly to moderately decreased 45–59 + ++ +++
G3b Moderately to severely
decreased
30–44 ++ +++ +++





G5 Kidney failure <15 +++ +++ +++
ACR = urinary albumin/creatinine ratio; CKD = chronic kidney disease; GFR = glomerular filtration rate; KDIGO = Kidney Disease: Improving Global Outcomes
+/– low risk (if no other markers of kidney disease, no CKD)
+ moderately increased risk
++ high risk
+++ very high risk
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antidiabetic drugs is recommended only with an eGFR <60
ml/min/1.73 m2, and equations are less reliable for eGFRs
>60 ml/min/1.73 m2, we chose to group values over 60
ml/min/1.73 m2 as CKD stages 1–2. CKD stages were
possible to calculate in only 1 354 patients because 5 pa-
tients had unreliable values, presumably owing to an error
of data entry. Estimated GFR was ≥60 ml/min/1.73 m2 in
77.6% of patients. CKD stages 3a, 3b and 4 were present
in 13.9%, 6.1%, and 2.4%, respectively. Nobody presen-
ted with CKD stage 5. By plotting the CKD stages accord-
ing to age and sex (fig. 1), it was possible to estimate the
age- and sex-related decline in renal function, using simple
linear regression. The estimated decline in renal function
was –1.15 (0.05) ml/min/1.73m2/y (p <0.001) for men and
–1.03 (0.06) ml/min/1.73 m2/y (p <0.001) for women. For
the evaluation of albuminuria, only 416 patients (30.6% of
total) had an entry for ACR. Of these, 35.6% were in CKD
stage A2 and 4.1% in stage A3. When an eGFR of <60 ml/
min/1.73 m2 and/or the presence or albuminuria were con-
sidered to indicate the presence of significant nephropathy,
45.4% of diabetic patients had significant nephropathy and
22.4% needed adjusted antidiabetic therapies according to
Swiss recommendations because of an eGFR <60 ml/min/
1.73 m2. More than 70% were reported to follow a healthy
way of life throughout all CKD stages.
Antidiabetic therapy and chronic kidney disease stages
Metformin and DPP-4 (dipeptidyl-peptidase-4) inhibitors
were the two most commonly prescribed oral antidiabetic
therapies (74% and 34.2% respectively), whereas the use of
sulfonylureas was less frequent (20.5%). Insulin was pre-
scribed in 28.9% of cases. Among the 1 359 patients, 6.3%,
37.7%, 38.3%, 15.7% and 1.9%, respectively, had no, one,
two, three and four pharmacological antidiabetic therapies
(fig. 2a). Because over three-quarters of individuals were
either on mono- or dual therapy, we chose to examine more
precisely which classes of antidiabetic therapy were pre-
scribed. Metformin was the preferred option for monother-
apy (57.1%) followed by insulin (19.8%) and sulfonylur-
eas (9.2%) (fig. 2b). The combination of metformin and a
DPP-4 inhibitor was the preferred option for dual therapy
(47.3%) followed by metformin and insulin (22.1%) and
metformin and a sulfonylurea (14.3%) (fig. 2c).
The prescription of each class of antidiabetic therapy ac-
cording to CKD stage is presented in figure 3. Metformin
was the preferred option at all stages of CKD except for
CKD stage 4. In spite of the prevailing contraindications
for its use in CKD stage 3b or more, metformin was pre-
scribed in 57.8% and 43.8%, respectively, of patients with
CKD stages 3b or 4. DPP-4 inhibitors were prescribed
approximately the same at all CKD stages, with a slight
trend towards more use with advancing CKD stages (34%,
33.5%, 37.3%, 37.5% for stages 1–2, 3a, 3b and 4, respect-
ively). Insulin use increased progressively from 26.8% in
CKD stage 1–2 to 50% in CKD stage 4. Sulfonylureas were
prescribed in 21.0%, 20.7%, 19.3% and 9.4% for stages
1–2, 3a, 3b and 4, respectively. GLP-1 (glucagon-like pep-
tide-1) agonists were prescribed in 7.0%, 4.8%, 1.2% and
3.1% for stages 1-2, 3a, 3b and 4, respectively. Prescrip-
tions of glinides, glitazones and alpha-glucosidase inhibit-
ors were all under 5% throughout CKD stages. Inappropri-
ate therapy with regard to eGFR was frequently observed,
especially for metformin in patients with CKD stage 3b or
more (table 3).
Regarding the question about hypoglycaemia, 611 answers
were missing. While stratifying the response according to
CKD stage, we chose to group low, medium and high fre-
quency as “yes” and never as “no”. Among the 748 pa-
tients who answered to the question about hypoglycaemia,
the prevalence of patients with episodes of hypoglycaemia
were increased at CKD stages 3 and 4 (25%, 34%, 61.4%
and 47.6% in CKD stages 1–2, 3a, 3b and 4, respectively)
(fig. 4) and was significantly correlated with CKD stage (p
<0.0001).
Table 2: Characteristics of type 2 diabetic patients enrolled in the study.
Number % Mean
(standard deviation)
Sex: M/F 782/577 57.5/42.5
Ethnicity: C/A 1 338/21 98.5/1.6
Age (y) 1 359 66.5 (12.4)
<40 y 34 2.5
40–60 y 335 24.7
60–80 y 781 57.5
>80 y 209 15.4
Duration of diabetes (y) 9.3 (8.8)
Body mass index (kg/m2) 30.2 (5.7)
<25 kg/m2 217 16
25–30 kg/m2 537 39.5
30–35 kg/m2 364 26.8
35–40 kg/m2 152 11.2
>40 kg/m2 88 6.5
CKD stage (GFR in ml/min/1.73 m2):
Stage 1–2 (≥60) 1 051 77.6
Stage 3a (45–59) 188 13.9
Stage 3b (30–44) 83 6.1
Stage 4 (15–29) 32 2.4
A = African descent; C = Caucasian; CKD = chronic kidney disease; F = female; GFR = glomerular filtration rate; M = male
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Antidiabetic therapy in diabetic patients treated in primary care
practices. Number of classes prescribed (2a), classes of drugs
prescribed as monotherapy (2b), classes of drugs prescribed as
dual therapy (2c).
DPP-4 = dipeptidyl-peptidase-4 inhibitor; GLP-1 = glucagon-like
peptide-1 agonist; met = metformin; SU = sulfonylurea
Figure 3
Antidiabetic class prescriptions (%) and chronic kidney disease
(CKD) stage.
DPP-IV = dipeptidyl-peptidase-4; GLP-1 = glucagon-like peptide-1
Figure 4
Presence of hypoglycaemia and chronic kidney disease (CKD)
stage.
Table 3: Inappropriate antidiabetic therapies according to prevailing recommendations.
Drug and recommendations % prescriptions
Metformin in CKD stage ≥3b 53.9%
Sulfonylurea in CKD stage ≥3b* 16.5%
GLP-1 in CKD stage ≥4 3.1%
Inappropriate dual therapy:
Sulfonylurea and glinide 0.2%
GLP-1 agonist and DPP-4 inhibitor 0.5%
CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; GLP-1 = glucagon-like peptide-1; DPP-4 = dipeptidyl peptidase-4
* Sulfonylureas are contraindicated in CKD stage 3 except for gliclazide, which can be given until an eGFR of 40 ml/min. For simplification, we examined the prescriptions
in CKD stage ≥3b
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Prevalence of significant chronic kidney disease in type
2 diabetes treated in primary care practices in
Switzerland.
To our knowledge, this study is the first to assess CKD pre-
valence and diabetes management in T2D patients treated
in a primary care setting in Switzerland. We found that
CKD stage 3–5 is common in T2D patients (22.4%). This is
in agreement with a recent USA observational study which
reported a CKD stage 3–5 prevalence of 25.8% in a popu-
lation of 9 339 T2D patients treated by primary care phys-
icians [4]. In contrast, this prevalence was much lower in
Finland (16.2%) in a study with a similar design but a smal-
ler number of patients than ours [5]. The estimated de-
cline in renal function was –1.15 (0.05) ml/min/1.73 m2/y
(p <0.001) for men and –1.03 (0.06) ml/min/1.73 m2/y (p
<0.001) for women, much higher than the estimated de-
cline in the general population Colaus study (–0.58 ml/min/
1.73 m2/y; average age = 51.1 y) [6], or the decline among
the Colaus 65–75-year-old group (–0.91 ml/min/1.73 m2/y,
Murielle Bochud, Peter Vollenweider personal communic-
ation, unpublished results).
When combining patients with both eGFR and ACR values
available, the rate of CKD stage 3–5 and/or albuminuria,
was 45.4% in Switzerland and 34.7% in the Finnish study
[5]. However, this rate could be inaccurately estimated in
our study as ACR values were available for only 30.6%
of patients. Underutilisation of ACR annual screening in
T2D patients followed-up in primary care has previously
been reported. In a cross-sectional study conducted in 2004
in the French-speaking part of Switzerland, annual screen-
ing for albuminuria was performed in only 49% of patients
[7]. Similarly, a more recent retrospective Swiss study of
T2D patients admitted to a general internal medicine clinic
in 2009 showed a screening rate of 56% in patients with
new onset diabetes and 66% in patients with previously
diagnosed T2D [8]. In a USA primary care setting, ACR
testing was performed in only 47.1% of T2D patients [4].
These results further emphasise the need to improve
primary care physician adherence to routine screening and
follow-up of diabetic nephropathy using both eGFR and
ACR, as recommended by current guidelines [9].
Patterns of prescribed antidiabetic regimens in
primary care practice
In our study, metformin was the preferred option overall
(74%), as monotherapy (57.1%) or dual therapy (92.7%).
Our data are in line with those from the United Kingdom
primary care setting, in which close to 90% of patients re-
ceived metformin as initial monotherapy or combination
therapy [10]. These practices are in accordance with cur-
rent American Diabetes Association / European Associ-
ation for the Study of Diabetes (ADA-EASD) guidelines
(2015), which recommend metformin as first-line pharma-
cological therapy in T2D [11]. The other monotherapy op-
tions included insulin (19.8%), sulfonylureas (9.2%) and
DPP-4 inhibitors (5.9%). The reason why each class was
chosen as monotherapy instead of metformin was not in-
vestigated in the present study. According to ADA-EASD
guidelines, if metformin is contraindicated or poorly toler-
ated, physicians should consider one of the six other classes
including insulin [11]. At the time of the study, there was
no scientific evidence supporting superiority of any anti-
diabetic class as second choice. When prescribing antidia-
betic therapy, physicians need to take into account efficacy,
hypoglycaemia risk, effect on weight, side effects, costs
and patient preference. According to the UK National In-
stitute for Health and Care Excellence (NICE) guidelines,
sulfonylureas can also be considered as first-line therapy in
nonobese patients, or when a rapid response to therapy is
required because of severe hyperglycaemia [12].
Most patients in our study were on dual therapy. In patients
with long-standing and complicated diabetes, a combined
regimen of antidiabetic drugs is often required to achieve
glycaemic targets. Among dual therapies, combination of
metformin and a DPP-4 inhibitor was the preferred option,
probably because both target different pathways without
the sulfonylurea or insulin side effects of weight gain and
hypoglycaemia.
Appropriateness of prescription of antidiabetic agents
according to degree of renal impairment
The kidneys are involved in the metabolism and clearance
of almost all antidiabetic agents [2]. Therefore, prescribing
antidiabetic drugs in patients with diabetes and CKD is
challenging, with special concerns regarding safety issues
and the need for appropriate dosage adjustment according
to eGFR.
Metformin is currently recommended as first-line pharma-
cological therapy in T2D unless there are contraindications
[11]. Contraindications to metformin use mainly relate to
renal function as this drug is primarily excreted unchanged
by the kidney. Renal failure leads to drug accumulation that
potentially enhances the risk of lactic acidosis, a rare (4.3/
100 000 patient/years) but potentially fatal condition [13].
The SSED clinical practice guidelines, published in 2012
and valid when the study was conducted, propose a cut-
off of eGFR <45 ml/min/1.73 m2 for stopping metformin
[2]. In contrast, other guidelines (NICE, ADA-EASD, Ca-
nadian Diabetes Association) allow metformin use with
great caution in stable CKD stage 3b only with appropriate
dosage reduction and close monitoring of renal function
[14–16]. The Swiss label for metformin (Glucophage®)
has consequently been updated to emphasise that metform-
in may be maintained in moderate stable CKD (eGFR
30–60 ml/min/1.73 m2) with dosage reduction (maximum
dosage 1 000 mg/d), and close monitoring of eGFR, unless
there are conditions that interfere with the metabolism/ex-
cretion of lactic acid (liver disease, heart failure, acute ill-
ness).
Despite prevailing limitations with regard to renal function,
our study showed that the use of metformin in T2D patients
with CKD stage 3b or more was very common (53.9%). In
real-life practice, poor adherence to the metformin label /
guidelines for kidney impairment has been reported world-
wide, ranging between 4.5–30% in outpatient settings
[17–21]. The OREDIA French cross-sectional observation-
al study reported metformin use in 33% of T2D patients
with renal contraindications (eGFR <30 ml/min/1.73 m2)
[17]. Also, the USA retrospective database analysis of
344 770 outpatient electronic medical records showed that
metformin was used in 21.5%, 19.8% and 20.1%, respect-
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ively of patients with moderate, severe and end-stage CKD
[18].
This study was not intended to assess the theoretical know-
ledge of primary care physicians on diabetic CKD manage-
ment. Inaccurate renal function assessment, under-recogni-
tion/awareness of CKD as well as lack of application of
guidelines, rather than lack of knowledge, could be pos-
sible explanations for inappropriate prescription of met-
formin in CKD [4, 17]. The aim of the original metformin
label was to provide a margin of safety to minimise the
risk of metformin-associated lactic acidosis. However, is-
sues of safe use of metformin in moderate CKD (stage
3) are being questioned and the cut-off for renal safety
is controversial. A recent systematic review assessed the
risk of metformin-associated lactic acidosis in patients with
impaired renal function [22]. This review found that: (i)
although metformin clearance is decreased proportionally
with eGFR decline, drug levels remain generally within
therapeutic range without a significant increase in lactate
levels when eGFR is >30 ml/min/1.73 m2; (ii) data suggest-
ing increased risk of lactic acidosis in metformin-treated
patients with CKD are limited; (iii) no randomised con-
trolled trial has been conducted to assess the safety of met-
formin in significantly impaired kidney function. Experts
supporting metformin use in moderate CKD argue that, if
metformin is avoided in moderate CKD because of the fear
of lactic acidosis, alternative use of sulfonylureas or insulin
may enhance the mortality/morbidity risk associated with
hypoglycaemia. Moreover, limited observational data sug-
gest cardiovascular benefits of metformin in patients with
moderate CKD compared with other antidiabetic agents
[23, 24]. In our opinion, it is important to continue to edu-
cate physicians and patients on the risk of metformin use
in CKD and in specific situations with risk of acute kidney
injury.
Sulfonylureas can be used as second-line therapy in com-
bination with metformin if the glycated haemoglobin target
is not achieved [10]. In our study, dual therapy with sulf-
onylureas or glinides and metformin were not the preferred
option, presumably because of the risk of hypoglycaemia
and weight gain. Renal failure is an independent risk factor
of hypoglycaemia and thus iatrogenic hypoglycaemia is a
major concern [25]. We found a significant increase in hy-
poglycaemic risk with advancing CKD stages. In Switzer-
land, gliclazide is the only sulfonylurea that can be used
in patients with eGFR 40–60 ml/min/1.73 m2 [2]. In our
study, sulfonylurea use did not decrease in patients with
CKD stage 3a and was inappropriate (in CKD stages 3b–4)
in 16.5% of cases. This is consistent with OREDIA data,
which reported that over 20% of patients were still taking
sulfonylureas despite prevailing renal contraindications
(eGFR <30 ml/min/1.73 m2) [16]. Similar findings were
seen in the RIACE study and the USA EMR-based ana-
lysis, where the use of sulfonylureas remained frequent in
severe CKD (18.1% and 22%, respectively) [17, 24].
DPP-4 inhibitors are incretin-based therapies approved in
Europe since 2007. They are positioned as second-line
therapy after metformin [10]. In Switzerland, available
DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin,
alogliptin, linagliptin) are approved and used across all
stages of CKD including end-stage renal disease (except
for saxagliptin). All need dosage adjustments with declin-
ing eGFR except for linagliptin, which can be adminis-
trated at all CKD stages at a dose of 5 mg daily [2]. In
our study, DPP-4 inhibitor use was relatively frequent at all
CKD stages (over one third of patients) increasing more in
CKD stage 3b–4, which is in agreement with the current
ADA consensus conference on diabetic kidney disease
[26]. Some emerging data suggest potential renoprotective
effects with linagliptin and saxagliptin (decrease in ACR),
independent of their glucose lowering effects [27, 28], and
larger clinical trials are underway to assess this issue fur-
ther. Cardiovascular safety of DPP-4 inhibitors was demon-
strated in three large dedicated trials [28–30]. In our view,
physicians need to be cautious with the prescription of
DPP-4 inhibitor therapy in diabetic patients with advanced
CKD and a history of heart failure [29, 30].
Currently available GLP-1 agonists (exenatide, liraglutide,
dulaglutide) are injectable incretin-based therapies used as
second- or third-line therapy [10]. Renal impairment may
alter the pharmacokinetic properties of exenatide leading to
decreased renal elimination and higher systemic exposure.
The clinical experience in CKD patients is quite limited.
Moreover, several case reports of GLP-1 agonist induced
acute kidney failure due to either acute tubulointerstitial
nephritis or acute tubular necrosis (trigged in part by de-
hydration resulting from the gastrointestinal and diuretic
effects of these drugs) raised some renal safety concerns
[31]. In Switzerland, GLP-1 receptor agonists are contrain-
dicated if eGFR <30 ml/min/1.73 m2 and should be used
with great caution with eGFR of 30–60 ml/min/1.73 m2,
especially in the elderly and in the case of diuretic and/or
renin-angiotensin system inhibitor treatment [2]. Patients
should be educated to report rapidly situations with in-
creased risk of dehydration. In our study, GLP-1 agonist
therapy was appropriate in most cases.
Glitazones were rarely used in our study population across
all CKD stage, presumably because Swissmedic (the Swiss
Agency for Therapeutic Products) has limited their use to
2 years because of the safety signal regarding bladder can-
cer. Moreover, pioglitazone use in CKD can aggravate wa-
ter and sodium retention.
In our study, close to half of the patients with CKD stage
4 were on insulin therapy. Insulin can be used at all CKD
stages; however, prevention of insulin-induced hy-
poglycaemia especially in the elderly is a critical issue [32].
Total insulin requirements are generally reduced when
eGFR falls below 60 ml/min/1.73 m2, because the kidneys
clear about 25–50% of circulating insulin [31]. Data on
pharmacokinetics and pharmacodynamics of insulin pre-
parations in patients with CKD are scarce. Basal insulin
analogues are the preferred option in T2D patients with
CKD over NPH insulin as the former were reported to
offer less variability and less hypoglycaemia in T2D pa-
tients with a history of frequent overnight hypoglycaemia
[33]. CKD diabetic patient education should focus on fre-
quent self-monitoring of blood glucose and prevention of
hypoglycaemia.
Limitations of the study: We cannot exclude that physicians
accepting to participate to the study were more compliant
with current recommendations than those who refused.
Furthermore, patients selected for data collection obviously
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represent a group more adherent to visits to physician of-
fices and in this case men may be underrepresented. Al-
though type 1 diabetes was an exclusion criterion, we can-
not exclude that some patients with latent autoimmune
diabetes in adults or with chronic pancreatitis were in-
cluded in the study, which may have biased the results to-
ward a higher prescription of insulin. When creatinine is
measured within the primary care practice, eGFR is regret-
tably not always calculated and can be a cause of unaware-
ness by primary care physicians of chronic kidney disease,
which may explain some misleading prescriptions. In this
study, we do not have the proportion of primary care phys-
icians relying on eGFR for their patient evaluation. Estim-
ated GFR may have been slightly overestimated in the 40%
of patients over 70 years of age with the CKD-EPI [34].
The reported frequency of following a “healthy way of life”
may have been overestimated as no detail was provided on
how the specific counselling was done.
Conclusions
CKD is frequent in T2D patients attending primary care
practices, with advanced CKD (eGFR <60 ml/min/1.73 m2)
present in 22.4% of cases. This emphasises the importance
of routine screening for and follow-up of diabetic neph-
ropathy based on both eGFR and ACR, the latter being
largely underused in primary care in Switzerland.
Accurate renal function evaluation and a careful individual
drug risk/benefit balance assessment are mandatory to
avoid the frequently observed inappropriate antidiabetic
therapy. In CKD diabetic patients attending primary care
physicians in Switzerland, metformin was the preferred op-
tion followed by DPP-4 inhibitors, insulin and sulfonylur-
eas. However, metformin was frequently prescribed in ad-
vanced CKD. Safety of metformin (lactic acidosis) in mod-
erate CKD is controversial. In our opinion, metformin can
be used with great caution in moderate and stable CKD
with dosage reduction, careful monitoring of eGFR, and
appropriate patient education to stop treatment transiently
if at risk of dehydration.
The new class of DPP-4 inhibitors is an interesting altern-
ative when metformin is contraindicated in CKD patients,
although ongoing safety studies have not yet shown any
superiority to other AD therapy in terms of cardiovascular
outcomes or renal function decline.
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Figures (large format)
Figure 1
Beta coefficient and standard error (SE) from simple linear regression.
CI = confidence interval; CKD-EPI = chronic kidney disease-epidemiology collaboration
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Antidiabetic therapy in diabetic patients treated in primary care practices. Number of classes prescribed (2a), classes of drugs prescribed as
monotherapy (2b), classes of drugs prescribed as dual therapy (2c).
DPP-4 = dipeptidyl-peptidase-4 inhibitor; GLP-1 = glucagon-like peptide-1 agonist; met = metformin; SU = sulfonylurea
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Figure 3
Antidiabetic class prescriptions (%) and chronic kidney disease (CKD) stage.
DPP-IV = dipeptidyl-peptidase-4; GLP-1 = glucagon-like peptide-1
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Figure 4
Presence of hypoglycaemia and chronic kidney disease (CKD) stage.
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